Stage‐Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real‐World Cohort Study From KAMU ‐ ON
- 25 August 2026
- journal article
- research article
- Published by Wiley in International Journal of Urology
- Vol. 33 (8) , e70617
Abstract
Objectives: To evaluate stage‐specific temporal trends in treatment patterns and overall survival (OS) among patients with prostate cancer in a Japanese multicentre cohort. Methods: This multicentre retrospective cohort study used data from the Kaga Million Uro‐Oncology Network (KAMU‐ON) registry. Patients diagnosed with prostate cancer between 2010 and 2024 were categorized as localized, nonmetastatic advanced, or metastatic disease. OS was assessed using Kaplan–Meier analyses and multivariable Cox proportional hazards models adjusted for clinically relevant covariates. Additional analyses with follow‐up administratively restricted at 48 months were performed. Results: A total of 7140 patients with defined disease stage and available survival data were included, comprising 5048 patients with localized disease, 1128 with nonmetastatic advanced disease, and 964 with metastatic disease. Treatment patterns changed substantially across diagnostic eras. Survival improvement appeared most evident in metastatic disease, whereas temporal differences were less apparent in nonmetastatic advanced disease. In multivariable Cox analyses, later diagnostic eras were associated with lower hazards of death in the overall cohort (2014–2017: HR 0.90, 95% CI 0.76–1.08; 2018–2024: HR 0.79, 95% CI 0.64–0.98). Formal interaction testing did not demonstrate statistically significant effect modification according to disease stage ( p = 0.163). Conclusions: Temporal survival trends in prostate cancer appeared to vary across disease stages in this Japanese multicentre cohort. Survival improvement appeared most evident in metastatic disease, whereas changes were less pronounced in nonmetastatic advanced disease. These findings suggest that therapeutic advances may not uniformly translate into survival gains across prostate cancer disease states.Keywords
This publication has 16 references indexed in Scilit:
- Trends in net survival for prostate cancer in Japan, 2000–14 (CONCORD-3)Japanese Journal of Clinical Oncology, 2026
- Initial treatment and resource utilization among patients with metastatic-castration sensitive prostate cancer in Japan: a retrospective real-world studyJapanese Journal of Clinical Oncology, 2024
- Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional studyJapanese Journal of Clinical Oncology, 2024
- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2022
- Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based studyActa Oncologica, 2019
- Apalutamide for Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2019
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countriesThe Lancet, 2018
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerNew England Journal of Medicine, 2017
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNew England Journal of Medicine, 2017
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerNew England Journal of Medicine, 2015